Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Susan Brouwer"'
Autor:
Fang Wang, Jane B. Trepel, Serap Sankoh, Peter Ordentlich, Lei Wang, Emmett V. Schmidt, Mateusz Opyrchal, Suresh S. Ramalingam, Min-Jung Lee, Pasi A. Jänne, Dmitry I. Gabrilovich, Elaine Shum, David Tamang, Navid Hafez, Sunmin Lee, Matthew D. Hellmann, Akira Yuno, Susan Brouwer, Michael L. Meyers, Luis E. Raez
Publikováno v:
Clin Cancer Res
Purpose: New therapies are needed to treat immune checkpoint inhibitor–resistant non–small cell lung cancer (NSCLC) and identify biomarkers to personalize treatment. Epigenetic therapies, including histone deacetylase inhibitors, may synergize wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04596a3f0e4f92bfa08108aa9a9ca260
https://pubmed.ncbi.nlm.nih.gov/33203644
https://pubmed.ncbi.nlm.nih.gov/33203644
Autor:
Susan Brouwer, Brian Berman, Shobha Ravipaty, R. Ye, Shari Goldfarb, Jason A. Konner, Janice Stevens, Niven R. Narain, Sarah Kitts, Viswanath Reddy Belum, Rangaprasad Sarangarajan, Mario E. Lacouture, Kathryn Ciccolini, V.R. Akmaev, Joaquin J. Jimenez
Publikováno v:
Cancer Research. 77:P5-11
Background: Chemotherapy induced alopecia (CIA) may lead to significant psychosocial and quality of life issues. Currently there are no FDA approved oral or topical agents available to prevent CIA. In murine studies, topical calcitriol reduced CIA, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4b8435ba5d956990c0f355c12311b05
https://doi.org/10.1158/1538-7445.sabcs16-p5-11-11
https://doi.org/10.1158/1538-7445.sabcs16-p5-11-11
Autor:
Michael L. Meyers, Melissa Lynne Johnson, Stergios J. Moschos, Mateusz Opyrchal, Peter Ordentlich, Susan Brouwer, Sanjiv S. Agarwala, Serap Sankoh, Ryan J. Sullivan
Publikováno v:
Cancer Research. 79:CT072-CT072
Background: Inhibitors of programmed death 1 (PD-1) and its ligand (PD-L1) have improved outcomes in patients (pts) with advanced melanoma, but treatment options for pts who progress on or after these therapies remain limited. In this group, we previ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4282e1405a501904b8df0b318718b4f3
https://doi.org/10.1158/1538-7445.am2019-ct072
https://doi.org/10.1158/1538-7445.am2019-ct072
Autor:
Gini F. Fleming, John W. Moroney, Serap Sankoh, Michael L. Meyers, Robert M. Wenham, Susan Brouwer, Robert A. Burger, Michael S. Gordon, Peter Ordentlich, Carol Aghajanian, Ursula A. Matulonis, Linda R. Duska, Erika Hamilton, Karen Cadoo, Richard T. Penson, Deborah K. Armstrong
Publikováno v:
Journal of Clinical Oncology. 37:5511-5511
5511 Background: Preclinical evidence suggests that combining avelumab (A), a human anti-PD-L1 monoclonal antibody, and entinostat (E), a class I selective histone deacetylase (HDAC) inhibitor, may increase tumor immunogenicity and responsivity to ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71ab682caa95679af1a11186fa0576f0
https://doi.org/10.1200/jco.2019.37.15_suppl.5511
https://doi.org/10.1200/jco.2019.37.15_suppl.5511
Autor:
Mateusz Opyrchal, Matthew D. Hellmann, Susan Brouwer, Michael L. Meyers, Fang Wang, Luis E. Raez, Dmitry I. Gabrilovich, Suresh S. Ramalingam, Leena Gandhi, Peter Ordentlich, Navid Hafez, Pasi A. Jänne, Serap Sankoh, Igor I. Rybkin, Emmett V. Schmidt
Publikováno v:
Journal of Clinical Oncology. 36:9036-9036
9036Background: Treatment options are limited in pts who progress on anti-PD-(L)1 therapy. HDAC inhibitors have the potential to modulate myeloid-derived suppressor cell (MDSC) function and may syn...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06bd97e80c859c4e01bfb7441e55299a
https://doi.org/10.1200/jco.2018.36.15_suppl.9036
https://doi.org/10.1200/jco.2018.36.15_suppl.9036
Autor:
Mateusz Opyrchal, Peter Ordentlich, Susan Brouwer, Nilofer S. Azad, Michael L. Meyers, Melissa Lynne Johnson, Autumn J. McRee, Serap Sankoh, Emmett V. Schmidt, Keisuke Shirai, Douglas B. Johnson
Publikováno v:
Journal of Clinical Oncology. 36:3557-3557
3557Background: In studies reported to date, no objective responses have been observed with PD-1 inhibitors in advanced/metastatic CRC (mCRC) pts with microsatellite stable (MSS)/mismatch repair pr...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3f9f63832c3edd6510c47f9de86982c
https://doi.org/10.1200/jco.2018.36.15_suppl.3557
https://doi.org/10.1200/jco.2018.36.15_suppl.3557
Autor:
Mateusz Opyrchal, Peter Ordentlich, Susan Brouwer, Sanjiv S. Agarwala, Serap Sankoh, Melissa Lynne Johnson, Michael L. Meyers, Emmett V. Schmidt, Dmitry I. Gabrilovich, Rene Gonzalez
Publikováno v:
Journal of Clinical Oncology. 35:9529-9529
9529 Background: Entinostat is an oral, class I selective histone deacetylase inhibitor shown preclinically to enhance immune checkpoint inhibitor activity by regulation of immune suppressor cells in the tumor microenvironment. ENCORE 601 is designed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38243ca5e0fe7b7ef5e529e9e9f4fa6b
https://doi.org/10.1200/jco.2017.35.15_suppl.9529
https://doi.org/10.1200/jco.2017.35.15_suppl.9529
Autor:
Shari Goldfarb, Brian Berman, Rangaprasad Sarangarajan, Kathryn Ciccolini, Niven R. Narain, Viacheslav R Akmaev, Joaquin J. Jimenez, Susan Brouwer, Ran Ye, Mario E. Lacouture, Jason A. Konner, Janice Stevens, Viswanath Reddy Belum, Sarah Kitts, Shobha Ravipaty
Publikováno v:
Journal of Clinical Oncology. 34:2564-2564
2564Background: Cancer patients receiving taxane-based chemotherapy develop alopecia, which may lead to significant psychosocial, quality of life, and adherence issues. Besides a recently FDA-clear...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f467b81c4a7ee2cbeba7444981f3dea
https://doi.org/10.1200/jco.2016.34.15_suppl.2564
https://doi.org/10.1200/jco.2016.34.15_suppl.2564
Autor:
Peter Paul Yu, Rangaprasad Sarangarajan, Janice Stevens, Gregory M Miller, Niven R. Narain, Vivek Subbiah, Ralph Zinner, Yezhou Sun, Eric M. Grund, Leonardo O. Rodrigues, Manish A. Shah, Susan Brouwer, Michael A. Kiebish, Viacheslav R Akmaev, Vivek K. Vishnudas
Publikováno v:
Journal of Clinical Oncology. 34:2550-2550
2550Background: BPM 31510 targets the metabolic machinery of cancer cells to reverse the Warburg effect. The current study evaluates BPM 31510 as a 6-day continuous infusion as a single agent and i...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff25253ee71d94a1a52115af6a8baa17
https://doi.org/10.1200/jco.2016.34.15_suppl.2550
https://doi.org/10.1200/jco.2016.34.15_suppl.2550
Autor:
Vivek K. Vishnudas, Peter Paul Yu, Leonardo O. Rodrigues, Niven R. Narain, Yezhou Sun, Janice Stevens, Ely Benaim, Rangaprasad Sarangarajan, Susan Brouwer, Michael A. Kiebish, Manish A. Shah, Ralph Zinner, Viatcheslav R. Akmaev
Publikováno v:
Cancer Research. 75:CT315-CT315
Background: BPM 31510 is a novel small molecule that targets the metabolic machinery of the cancer microenvironment to create a hallmark shift from lactate dependency towards mitochondrial oxidative phosphorylation, reversing the Warburg effect. Prec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47a7abf9f337538347605d4539aa2ac7
https://doi.org/10.1158/1538-7445.am2015-ct315
https://doi.org/10.1158/1538-7445.am2015-ct315